Results 71 to 80 of about 18,081 (213)

Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background and Aims Dyslipidemia is common in patients with MASLD, but the frequency and significance of inherited disorders of dyslipidemia are unclear. We investigated the prevalence and significance of pathogenic variants associated with selected monogenic disorders of dyslipidemia in 3358 patients with well‐characterised MASLD. Approach We
Tae‐Hwi Schwantes‐An, Marco A. Abreu, Brent A. Neuschwander‐Tetri, Jian Wang, Xiuqing Guo, Jingyi Tan, Robert A. Hegele, Nicholas O. Davidson, Luca Lotta, Niek Verweij, Katherine P. Yates, Jerome I. Rotter, Naga Chalasani   +12 more
wiley   +1 more source

Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9

Атеросклероз, 2015
The review presents the current data of scientific literature about different phases of clinical trials of monoclonal antibodies against the proprotein convertase subtilisin/kexin type 9 (PCSK9). The results of completed clinical trials and the review of
K. S. Astrakova, Yu. I. Ragino, E. V. Shakhtshneider, M. I. Voevoda   +3 more
doaj  

PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer [PDF]

, 2022
Frédéric Couture, Luojun Wang, Frédérik Dufour, Keena Chabot-Maheux, Nadia Ekindi Ndongo, Robert Sabbagh, Robert Day   +6 more
openalex   +1 more source

Receptor‐Dependent and ‐Independent Effects of Hemin on Platelet Plasma Membrane Disintegration

The FASEB Journal, Volume 40, Issue 2, 31 January 2026.
Microhemorrhages lead to the release of erythrocytes, which are then degraded and lysed. These hemolyses result in the liberation of free iron‐containing hemin. Hemin induces platelet activation and ferroptosis. Inhibition of GPVI/CLEC‐2 receptor‐mediated ITAM‐signaling inhibits hemin‐induced platelet activation (low hemin concentrations). Deferoxamine,
Zoi Laspa, Anne‐Katrin Rohlfing, Ravi Hochuli, Pamela Weronika Sowa, Tatsiana Castor, Meinrad Paul Gawaz   +5 more
wiley   +1 more source

Beyond lipids: Systemic effects of lipoprotein apheresis

Transfusion, EarlyView.
Menatalla Nadim, Yamac Akgun
wiley   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia

, 2021
А. А. Shikaleva, М. L. Maksimov, Н. М. Киселева   +2 more
openalex   +2 more sources

Proprotein Convertase Inhibition Results in Decreased Ski Proliferation, Tumorigenesis, and Metastasis

Neoplasia: An International Journal for Oncology Research, 2010
PACE4 is a proprotein convertase (PC) responsible for cleaving and activating proteins that contribute to enhance tumor progression. PACE4 overexpression significantly increased the susceptibility to carcinogenesis, leading to enhanced tumor cell ...
Daniel E. Bassi, Jirong Zhang, Jonathan Cenna, Samuel Litwin, Edna Cukierman, Andres J.P. Klein-Szanto   +5 more
doaj   +1 more source

Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions

Journal of Clinical and Preventive Cardiology, 2017
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol
JPS Sawhney, Saurabh Bagga
doaj   +1 more source

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

Vascular Health and Risk Management, 2017
Alberico Luigi Catapano,1,2 Angela Pirillo,1,2 Giuseppe Danilo Norata1,3,4 1Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 2IRCCS Multimedica Hospital, Sesto San Giovanni, 3Center for the Study of ...
Catapano AL, Pirillo A, Norata GD
doaj  

PCSK9: a convertase that coordinates LDL catabolism

Journal of Lipid Research, 2009
The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD).
Jay D. Horton, Jonathan C. Cohen, Helen H. Hobbs   +2 more
doaj   +1 more source